サポートされていないブラウザが使用されています。
このサイトの一部の機能が正しく機能しない可能性があります。最適なユーザーエクスペリエンスを得るために、このサイトはChrome、Firefox、Safari、またはEdgeで表示してください。

ニュースルーム

お知らせ

Date

Announcement

   
September 16, 2021

Repligen Announces Agreement to Acquire Avitide Inc. Read More

September 9, 2021

Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies
Read More

September 3, 2021

Repligen Extends Long Term Supply Agreement with Cytiva for Affinity Ligands. Read More

2021年6月22日

Repligen Corporation Announces Agreement to Acquire Polymem S.A. Read More

February 8, 2021

Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines. Read More

October 27, 2020

Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions. Read More

October 1, 2020

Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines. Read More

2020年6月29日

Repligen Announces Agreement to Acquire Engineered Molding Technology. Read More

April 26, 2019

Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies.  Read More

Septermber 4, 2018

Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors. Read More

2018年6月28日

Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand.  Read More

2018年6月27日

Repligen Announces Agreement with Navigo Proteins for the Exclusice Co-Development of Next Generation Affinity Ligands.  Read More

2017年6月23日

Repligen Corporation and Spectrum Inc. to Join Forces.  Read More

December 15, 2016

Repligen acquires TangenX Technology Corporation.  Read More

October 4, 2016

Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification.  Read More

April 4, 2016

Repligen acquires Atoll GmbH.  Read More

 

最近のニュース

Date

Title

刊行物

     

July 26, 2021

Repligen Corporation set to significantly expand bioprocessing manufacturing capactiy and create 130+ new jobs in Waterford

IDA Ireland

2021年6月13日

Repligen buys Frech filtraion firm Polymem Dan Stanton
BioProcess International

2021年5月19日

Coronavirus Spike Protein Captures Resin Available for Future Deployment GEN

February 12, 2021

New Affinity Resin for COVID-19 Vaccine Purification

GEN

February 10, 2021

Repligen and Navigo target next-wave COVID vaccines with affinity resin

Dan Stanton
BioProcess International
December 17, 2020

America's Best Mid-size Companies
Repligen: #15

Andrea Murphy, Hank Tucker
Forbes
November 19, 2020 Repligen CEO Tony Hunt Knows Why Success Takes Time Marilyn Munch
Investor's Business Daily
October 28, 2020 Repligen strengthens downstream offering with $200m ARTeSYN acquisition Dan Stanton
BioProcess International
October 8, 2020

Navigo and Repligen Team on COVID-19 Vaccine Affinity Resin

Dan Stanton
BioProcess International
September 1, 2020

Continuous Processing: A Step on the Way to Bioprocess 4.0

Gareth John Macdonald
GEN
July 1, 2020

Repligen boosting single-use portfolio with Engineered Molding Technology buy

BPI Staff
BioProcess International
February 24, 2020

Repligen up on OPUS® and Gene Therapy Demand

Dan Stanton
BioProcess International
October 1, 2019 Using Alternating Tangential Flow with Fed-Batch Cultures

GEN

August 12, 2019 Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application.

Samsung BioLogics’ cell culture technique to cut production life by 30%
 

Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application 

Samsung BioLogics implants cell-culturing tech
 
Samsung Biologics

Pulse News

Yahoo News

Korea Biomed
2019年5月20日 OPUS focus: Repligen expands to support chromatography demand Dan Stanton
BioProcess International

 


Press Contact

Sondra Newman
Senior Director, Investor Relations

press @ repligen.com

Phone: 781.250.0111
Toll-free: 800.622.2259
Fax: 781.250.0115

download repligen logo